Using benefit harm tradeoffs to estimate sufficiently important difference: The case of the common cold

Medical Decision Making

Volumn 25, Issue 1, 2005, Pages 47-55

  Barrett, Bruce ^a   Brown, Roger ^a   Mundt, Marion ^a   Dye, Leota ^a   Alt, Jennifer ^a   Safdar, Nasia ^a   Maberry, Rob ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Common cold; Controlled trials; Decision making; Evidence based medicine; Important difference; Patient preferences; Quality of life; Treatment outcome; Upper respiratory infection

Indexed keywords

ASCORBIC ACID; PLECONARIL; ZINC;

ADULT; AGED; ARTICLE; COMMON COLD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; ECHINACEA; FEMALE; HUMAN; HYPOTHESIS; INTERVIEW; LOZENGE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SIDE EFFECT; SYMPTOM; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; COMMON COLD; COSTS AND COST ANALYSIS; EDUCATIONAL STATUS; FEMALE; HUMANS; INCOME; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHARMACEUTICAL PREPARATIONS; PLANT PREPARATIONS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VITAMINS;

EID: 12344307226     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X04273147     Document Type: Article

References (63)

1. Deyo RA, Patrick DL. The significance of treatment effects: the clinical perspective. Med Care. 1995;33:AS286-AS291.
2. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-44.
3. Mitchell PH. The significance of treatment effects: significance to whom? Med Care. 1995;33:AS280-AS285.
4. Kirshner B, Guyatt GH. A methodological framework for assessing health indices. J Chron Dis. 1985;38:27-36.
5. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol. 1992;45:1341-5.
6. Guyatt GH, Bombardier C, Tugwell P. Measuring disease-specific quality of life in clinical trials. Can Med Assoc J. 1986;134:889-94.
7. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trial. 1989;10:407-15.
8. Graham NMH. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev. 1990;12:149-77.
9. Gwaltney JM. Rhinovirus colds: epidemiology, clinical characteristics and transmission. Eur J Respir Dis. 1983;64:336-9.
10. Dingle JH, Badger GF, Jordan WS. Illness in the Home: A Study of 25,000 Illnesses in a Group of Cleveland Families. Cleveland (OH): Press of Western Reserve University; 1964.
11. Gwaltney JM, Hendley JO, Simon G, Jordan WS. Rhinovirus infections in an industrial population. JAMA. 1967;202:158-64.
12. Monto AS, Ullman BM. Acute respiratory illness in an American community. JAMA. 1974;227:164-9.
13. Health and Human Services. Vital Health Statistics: Current Estimates from the National Health Interview Survey. Survey No. 190. Washington (DC): Health and Human Services; 1994.
14. Bertino JS. Cost burden of viral respiratory infections: issues for formulary decision makers. Am J Med. 2002;112:Suppl-49S.
15. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Int Med. 2003;163:487-94.
16. Falsey AR, McCann RM, Hall WJ, Griddle MM, Formica MA, Wycoff D, et al. The "common cold" in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center. J Am Geriatr Soc. 1997;45:706-11.
17. Pitkaranta A, Hayden FG. Rhinoviruses: important respiratory pathogens. Ann Med. 1998;30:529-37.
18. Gern JE, Busse WW. The role of viral infections in the natural history of asthma. J Allergy Clin Immunol. 2000;106:201-12.
19. Heiskanen-Kosma T, Korppi M, Jokinen C, Heinonen K. Risk factors for community-acquired pneumonia in children: a population-based case-control study. Scand J Infect Dis. 1997;29:281-5.
20. Alkhenizan A, Evans MF. Common colds complicated by acute sinusitis. Can Fam Physician. 1999;45:2887-8.
21. Loeb M, McGeer A, McArthur M, Walter S, Simor AE. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch Int Med. 1999;159:2058-64.
22. Jackson GG, Dowling HF, Muldoon RL. Present concepts of the common cold. Am J Public Health. 1962;52:940-5.
23. Kostka T, Berthouze SE, Lacour J-R, Bonnefoy M. The symptomatology of upper respiratory tract infections and exercise in elderly people. Med Sci Sports Exerc. 2000;32:46-51.
24. Rao SS, Hendley JO, Hayden FG, Gwaltney JM. Symptom expression in natural and experimental rhinovirus colds. Am J Rhinol. 1995;9:49-52.
25. Gwaltney JM, Buier RM, Rogers JL. The influence of signal variation, bias, noise and effect size on statistical significance in treatment studies of the common cold. Antiviral Res. 1996;29:287-95.
26. Barrett B, Locken K, Maberry R, Schwamman J, Bobula J, Brown R, et al. The Wisconsin Upper Respiratory Symptom Survey: development of an instrument to measure the common cold. J Fam Pract. 2002;51:265. Retrieved from www.jfponline.com.
27. Barrett B, Brown RL, Mundt MP, Safdar N, Dye L, Maberry R, et al. The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid. J Clin Epidemiol. 2004; accepted for publication.
28. Cohen S, Doyle WJ, Skoner DP, Fireman P, Gwaltney JM, Newsom JT. State and trait negative affect as predictors of objective and subjective symptoms of respiratory viral infections. J Pers Soc Psychol. 1995;68:159-69.
29. Linder JA, Singer DE. Health-related quality of life of adults with upper respiratory tract infections. J Gen Intern Med. 2003;18(10):802-7.
30. Fahey T, Stocks N, Thomas T. Systematic review of the treatment of upper respiratory tract infection. Arch Dis Child. 1998;79:225-30.
31. Smith MBH, Feldman W. Over-the-counter cold medications: a critical review of clinical trials between 1950 and 1991. JAMA. 1993;269:2258-63.
32. Turner RB. The treatment of rhinovirus infections: progress and potential. Antiviral Res. 2001;49:1-14.
33. Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomized controlled trials comparing antibiotic with placebo for acute cough in adults. BMJ. 1998;316:906-10.
34. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis. In: Cochrane Database of Systematic Reviews. Oxford (UK): Cochrane Database; 2003.
35. Taverner D, Bickford L, Draper M. Nasal decongestants for the common cold. In: The Cochrane Library, Issue 4. Oxford (UK): Update Software, The Cochrane Library; 2001.
36. Howard JC, Kantner TR, Lilienfield LS, Princiotto JV, Krum RE, Crutcher JE, et al. Effectiveness of antihistamines in the symptomatic management of the common cold. JAMA. 1979;242:2414-7.
37. De Sutter AIM, Lemiengre M, Campbell H, Mackinnon HF. Anti-histamines for the common cold (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford (UK): Update Software; 2003.
38. Douglas RM, Chalker EB, Treacy B. Vitamin C for preventing and treating the common cold. In: Cochrane Database of Systematic Reviews. Oxford (UK): Cochrane Database; 2003.
39. Hemila H. Does vitamin C alleviate the symptoms of the common cold? A review of current evidence. Scand J Infect Dis. 1994;26:1-6.
40. Godfrey JC, Godfrey NJ, Novick SG. Zinc for treating the common cold: review of all clinical trials since 1984. Alt Ther. 1996;2:63-72.
41. Marshall I. Zinc for the common cold. In: Cochrane Database of Systematic Reviews. Oxford (UK): Cochrane Database; 2003.
42. Jackson JL, Peterson C, Lesho E. A meta-analysis of zinc salt lozenges and the common cold. Arch Int Med. 1997;157:2373-6.
43. Barrett B, Vohmann M, Calabrese C. Echinacea for upper respiratory infection: evidence-based clinical review. J Fam Pract. 1999;48:628-35.
44. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. In: The Cochrane Library, Issue 4. Oxford (UK): Update Software, The Cochrane Library; 2000.
45. Giles JT, Palat CT, Chien SH, Chang ZG, Kennedy DT. Evaluation of Echinacea for treatment of the common cold. Pharmacotherapy. 2000;20:690-7.
46. Hayden FG, Coats T, Kim K, Hassman HA, Blatter MM, Zhang B, et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antiviral Ther. 2002;7:53-65.
47. Jefferson TO, Tyrrell D. Antivirals for the common cold. In: Cochrane Database of Systematic Reviews. Oxford (UK): Cochrane Database; 2003.
48. Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, George RSt, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection. JAMA. 1999;281:1797-804.
49. Ware JE, Kosinski M, Dewey JE, Gandek B. How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8 Health Survey. Lincoln (RI): QualityMetric; 2001.
50. Cunnington JP, Turnbull TM, Regehr G, Marriott M, Norman GR. The effect of presentation order in clinical decision making. Acad Med. 1997;72:Suppl-2.
51. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-83.
52. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14:109-14.
53. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston: Butterworth-Heinemann; 1988.
54. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981;211:453-8.
55. Froberg DG, Kane RL. Methodology for measuring health-state-preferences- I: Measurement strategies. J Clin Epidemiol. 1989;42:345-54.
56. Guyatt GH, Rennie D. Users' Guides to the Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press: 2002.
57. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. Edinburgh: Churchill Livingstone: 2000.
58. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials. JAMA. 2001;285:1992-5.
59. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group; 2001.
60. Llewellyn-Thomas HA. Patients' health-care decision making: a framework for descriptive and experimental investigations. Med Decis Making. 1995;15:101-6.
61. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol. 1994;47:787-95.
62. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making. 1996;16:262-82.
63. Llewellyn-Thomas HA. Investigating patients' preferences for different treatment options. Can J Nurs Res. 1997;29:45-64.